1. Home
  2. KALV vs AOSL Comparison

KALV vs AOSL Comparison

Compare KALV & AOSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • AOSL
  • Stock Information
  • Founded
  • KALV N/A
  • AOSL 2000
  • Country
  • KALV United States
  • AOSL United States
  • Employees
  • KALV N/A
  • AOSL N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • AOSL Semiconductors
  • Sector
  • KALV Health Care
  • AOSL Technology
  • Exchange
  • KALV Nasdaq
  • AOSL Nasdaq
  • Market Cap
  • KALV 796.4M
  • AOSL 847.8M
  • IPO Year
  • KALV N/A
  • AOSL 2010
  • Fundamental
  • Price
  • KALV $11.10
  • AOSL $31.90
  • Analyst Decision
  • KALV Strong Buy
  • AOSL Strong Buy
  • Analyst Count
  • KALV 8
  • AOSL 3
  • Target Price
  • KALV $26.43
  • AOSL $32.00
  • AVG Volume (30 Days)
  • KALV 1.5M
  • AOSL 260.7K
  • Earning Date
  • KALV 12-04-2025
  • AOSL 11-05-2025
  • Dividend Yield
  • KALV N/A
  • AOSL N/A
  • EPS Growth
  • KALV N/A
  • AOSL N/A
  • EPS
  • KALV N/A
  • AOSL N/A
  • Revenue
  • KALV $1,426,000.00
  • AOSL $696,162,000.00
  • Revenue This Year
  • KALV N/A
  • AOSL $4.57
  • Revenue Next Year
  • KALV $209.38
  • AOSL $7.67
  • P/E Ratio
  • KALV N/A
  • AOSL N/A
  • Revenue Growth
  • KALV N/A
  • AOSL 5.92
  • 52 Week Low
  • KALV $7.30
  • AOSL $15.90
  • 52 Week High
  • KALV $17.28
  • AOSL $53.29
  • Technical
  • Relative Strength Index (RSI)
  • KALV 38.98
  • AOSL 61.41
  • Support Level
  • KALV $10.75
  • AOSL $30.00
  • Resistance Level
  • KALV $12.23
  • AOSL $31.94
  • Average True Range (ATR)
  • KALV 0.62
  • AOSL 1.70
  • MACD
  • KALV -0.01
  • AOSL 0.39
  • Stochastic Oscillator
  • KALV 23.41
  • AOSL 84.63

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About AOSL Alpha and Omega Semiconductor Limited

Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.

Share on Social Networks: